Liposomal Chemotherapeutics

Christian Celia, Pharm.D., Ph.D. Department of Pharmacy, University of Chieti – Pescara, “G. d’Annunzio” Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA E-mail: c.celia@unich.it; Phone office: +39 0871 355 4711

ITEMS ✔ Introduction to Nanotherapeutics and Nanomedicines ✔ Lipid based Nanotherapeutics in Nanomedicines ✔ Conclusion

✔ Future Perspective

Introduction to Nanotherapeutics

K. Park. Journal of Controlled Release, 2014, 190, 3 – 8.

A. Babu, A.K. Templeton, A. Munshi, R. Ramesh. AAPS PharmSciTech, 2014, 15, 709 – 721.

A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.

A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.

A. Hafner, J. Lovrić, G.P. Lakoš, I. Pepić, International Journal of Nanomedicine, 2014, 9, 1005 – 1023.

http://www.slideshare.net/uapnazmul/liposomal-drug-delivery-system

K. Park. ACS Nano, 2013, 7, 7442 – 7447.

Lipid based Nanotherapeutics in Nanomedicines

Anticancer Therapy

A. Babu, A.K. Templeton, A. Munshi, R. Ramesh. AAPS PharmSciTech, 2014, 15, 709 – 721.

C.M. Dawidczyk, C. Kima, J.H. Park, L.M. Russell, K.H. Lee, M.G. Pomper, P.C. Searson, Journal of Controlled Release, 2014, 187, 133 – 144.

V. Sanna, N. Pala, M. Sechi, International Journal of Nanomedicine, 2014, 9, 467 – 483.

E. Gentile, F. Cilurzo, L. Di Marzio, M. Carafa, C.A. Ventura, J. Wolfram, D. Paolino, C. Celia., Future Oncology, 2013, 9, 1849 – 1859.

M.G. Calvagno, C. Celia, D. Paolino, D. Cosco, M. Iannone, F. Castelli, P. Doldo, M. Fresta, Current Drug Delivery 2007, 4, 89 – 101.

C. Celia, E. Trapasso, M. Locatelli, M. Navarra, C.A. Ventura, J. Wolfram, M. Carafa, V.M. Morittu, D. Britti, L. Di Marzio, D. Paolino, Colloids Surf B: Biointerfaces, 2013, 112, 548 – 553.

D. Paolino, D. Cosco, L. Racanicchi, E. Trapasso, C. Celia, M. Iannone, E. Puxeddu, G. Costante, S. Filetti, D. Russo, M. Fresta, Journal of Controlled Release, 2010, 144, 144 – 150.

D. Cosco, A. Bulotta, M. Ventura, C. Celia, T. Calimeri, G. Perri, D. Paolino, N. Costa, P. Neri, P. Tagliaferri, P. Tassone, M. Fresta, Cancer Chemotherapy and Pharmacology, 2009, 64, 1009 – 1020.

E. Gentile, F. Cilurzo, L. Di Marzio, M. Carafa, C.A. Ventura, J. Wolfram, D. Paolino, C. Celia., Future Oncology, 2013, 9, 1849 – 1859.

B.S. Brown, T. Patanam, K. Mobli, C. Celia, P.E. Zage, A.J. Bean, E. Tasciotti, Cancer Biology and Therapy, 2014, 15, 851 – 861.

B.S. Brown, T. Patanam, K. Mobli, C. Celia, P.E. Zage, A.J. Bean, E. Tasciotti, Cancer Biology and Therapy, 2014, 15, 851 – 861.

D. Paolino, D. Cosco, M. Gaspari, M. Celano, J. Wolfram, P. Voce, E. Puxeddu, S. Filetti, C. Celia, M. Ferrari, D. Russo, M. Fresta. Biomaterials, 2014, 35, 7101 – 7109.

D. Paolino, D. Cosco, M. Gaspari, M. Celano, J. Wolfram, P. Voce, E. Puxeddu, S. Filetti, C. Celia, M. Ferrari, D. Russo, M. Fresta. Biomaterials, 2014, 35, 7101 – 7109.

G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.

G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.

a, panel a shows the body distribution of SLs after in vivo injection in liver and blood; b, panel b shows the body distribution of SSL(4)s after in vivo injection in liver and blood.

1 1

G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Sciavon, H. Shen, M. Fresta, Journal of Controlled Release, 2015, 199, 106 – 113.

Nude SKID mice bearing MDA-MB-231 breast cancer bone metastasis cells treated by using Dox hydrochloride-loaded SSLs. The anticancer treatment is carried out for 5 weeks. Images are acquired per week. Animals are injected i.v. during the treatment. 5 animals per groups is used during the experiments. Key legends: A) PBS solution (control); B) empty SSLs; C) Doxorubicin hydrochloride; D) Doxorubicin hydrochloride-loaded SSLs. Quantification of tumor development and body weight in Nude SKID mice bearing MDA-MB-231 breast cancer bone metastasis cells treated by using Dox hydrochloride-loaded SSLs. Key legends: (●) PBS buffer solution; (▼) Empty SSLs; (■) Doxorubicin hydrochloride; (®) Doxorubicin hydrochloride-loaded SSLs. 5 animals per groups is used during the experiments.

Celia C, Huang Y, Pasut G, Paolino D, Ferrari M, Fresta M, Shen H. 2015; manuscript in preparation.

Celia C, Huang Y, Pasut G, Paolino D, Ferrari M, Fresta M, Shen H. 2015; manuscript in preparation.

D.K. Kirui, C. Celia, R. Molinaro, S.S. Bansal, D. Cosco, M. Fresta, H. Shen, M. Ferrari, Advanced Healthcare Materials, 2015, 4, 1092 – 1103.

D.K. Kirui, C. Celia, R. Molinaro, S.S. Bansal, D. Cosco, M. Fresta, H. Shen, M. Ferrari, Advanced Healthcare Materials, 2015, 4, 1092 – 1103.

J. Sih, S.S. Bansal, S. Filippini, S. Ferrati, K. Raghuwansi, E. Zabre, E. Nicolov, D. Fine, M. Ferrari, G. Palapattu, A. Grattoni. Analitical Bioanalitical Chemistry, 2013, 405, 1547 – 1557.

D. Fine, A. Grattoni, S. Hosali, A. Ziemys, E. De Rosa, J. Gill, R. Medema, L. Hudson, M. Kojic, M. Milosevic, L. Brousseau III, R. Goodall, M. Ferrari, X. Liu. Lab on Chip, 2010, 10, 3074 – 3083.

C. Celia, S. Ferrati, S. Bansal, A. L. van de Ven, B. Ruozi, E. Zabre, S. Hosali, D. Paolino, M.G. Sarpietro, D. Fine, M. Fresta, M. Ferrari, A. Grattoni. Advanced Healthcare Materials, 2014, 3, 230 – 238.

Conclusion ✔ Liposomes can significantly enhance the anticancer

efficiency of chemotherapeutics for the treatment of solid and blood-borne tumors.

✔ Liposomes can increase the circulation time, decrease side

effects, enhance tumor accumulation and overcome drug resistance of chemotherapeutics.

✔ Liposomes improve pharmacokinetic and biopharmaceutical

features of chemotherapeutics. ✔ Liposomes provide a customized chemotherapy in

innovative Nanomedicine. ✔ Liposomes are therapeutic tools for chemotherapeutic

treatment.

Future Perspective ✔Many more liposomal chemotherapeutics will gain clinical

approval in the near future. ✔Overcome the potential toxicity arising from the presence

of PEG on liposomal surface. ✔Overcome the high production costs in comparison with

conventional cytotoxic agents. ✔ Improve the number of Clinical Trails using liposomal

chemotherapeutics.

✔ Customize Selective Liposomal Chemotherapeutics.

Research Staffs and Collaborators

University of Catanzaro “Magna Græcia”, Italy Prof. Massimo Fresta Prof. Donatella Paolino Prof. Donato Cosco Dr. Felisa Cilurzo Dr. Maria Chiara Cristiano

The Methodist Hospital Research Institute, Houston, TX, USA

Prof. Mauro Ferrari Prof. Paolo Decuzzi Prof. Haifa Shen Prof. Alessandro Grattoni Prof. Rita Serda Prof. Ennio Tasciotti Dr. Aryal Santos Dr. Yi Huang Dr. Shyam Bansal Dr. Silvia Ferrati Dr. Dickson Kirui Dr. Krishna Suri Dr. Joy E Wolfram

University of Chieti- Pescara “G. d’Annunzio”, Italy

Prof. Luisa Di Marzio Prof. Marcello Locatelli Dr. Sara Esposito Dr. Martina Di Francesco Dr. Rosita Primavera

Research Staffs and Collaborators

University of Palermo

Prof. Gaetano Giammona Prof. Gennara Cavallaro Prof. Mariano Licciardi

University of Padua

Prof. Oddone Schiavon Prof. Gianfranco Pasut Dr. Anna Mero

University of Rome “La Sapienza”

Prof. Maria Carafa Prof. Carlotta Marianecci Dr. Federica Rinaldi